Matches in SemOpenAlex for { <https://semopenalex.org/work/W2150617926> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2150617926 endingPage "674" @default.
- W2150617926 startingPage "667" @default.
- W2150617926 abstract "Biological agents induce cutaneous adverse drug reactions (CADR) different from those observed with xenobiotics. Type alpha is the cytokine release syndrome, type beta are hypersensitivity reactions and type gamma is a cytokine imbalance syndrome. Infusion-reactions, anaphylactoid reactions occur with various biological agents administered intravenously. In non-severe cases the infusion rate has to be reduced, in severe reactions, the treatment must be stopped and resuscitation carried out with corticosteroids and epinephrine. Reactions may be due to an alpha syndrome but a true allergy could be involved as demonstrated in some patients with IgE antibodies to the galactose-alpha-1,3-galactose portion of the cetuximab or anti infliximab-IgE. Some desensitisation protocols have been published. Non allergic itching and eczema-like lesions are frequent with epidermal growth factor receptor inhibitors. Rash or desquamation was observed in 40% of cases with antiangiogenic agents, 90% of patients treated with imatinib have rashes, oedema or pruritus and a non-allergic periorbital oedema. Severe CADR, such as Stevens-Johnson syndrome, can be provoked. Delayed readings of intradermal tests could be of value in managing patients with a maculopapular rash due to interferon. Anaphylaxis attributed to omalizumab seems to be rare (0.2%) and skin rashes occur in 7% of cases. Anaphylactoid reactions occur in 1% of patients treated with natalizumab. In the case of anti-natalizumab antibody-mediated reactions, treatment should be stopped. These allergic-like side effects of new biological agents must be known and reported to Pharmacovigilance agency networks." @default.
- W2150617926 created "2016-06-24" @default.
- W2150617926 creator A5014491743 @default.
- W2150617926 creator A5042448793 @default.
- W2150617926 creator A5058964346 @default.
- W2150617926 creator A5081377789 @default.
- W2150617926 date "2011-09-01" @default.
- W2150617926 modified "2023-09-25" @default.
- W2150617926 title "How to manage hypersensitivity reactions to biological agents?" @default.
- W2150617926 doi "https://doi.org/10.1684/ejd.2011.1468" @default.
- W2150617926 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21742594" @default.
- W2150617926 hasPublicationYear "2011" @default.
- W2150617926 type Work @default.
- W2150617926 sameAs 2150617926 @default.
- W2150617926 citedByCount "28" @default.
- W2150617926 countsByYear W21506179262012 @default.
- W2150617926 countsByYear W21506179262013 @default.
- W2150617926 countsByYear W21506179262014 @default.
- W2150617926 countsByYear W21506179262015 @default.
- W2150617926 countsByYear W21506179262016 @default.
- W2150617926 countsByYear W21506179262017 @default.
- W2150617926 countsByYear W21506179262018 @default.
- W2150617926 countsByYear W21506179262019 @default.
- W2150617926 countsByYear W21506179262020 @default.
- W2150617926 countsByYear W21506179262021 @default.
- W2150617926 crossrefType "journal-article" @default.
- W2150617926 hasAuthorship W2150617926A5014491743 @default.
- W2150617926 hasAuthorship W2150617926A5042448793 @default.
- W2150617926 hasAuthorship W2150617926A5058964346 @default.
- W2150617926 hasAuthorship W2150617926A5081377789 @default.
- W2150617926 hasConcept C141105273 @default.
- W2150617926 hasConcept C159654299 @default.
- W2150617926 hasConcept C16005928 @default.
- W2150617926 hasConcept C203014093 @default.
- W2150617926 hasConcept C207480886 @default.
- W2150617926 hasConcept C2775933838 @default.
- W2150617926 hasConcept C2777995640 @default.
- W2150617926 hasConcept C2778168870 @default.
- W2150617926 hasConcept C2778564945 @default.
- W2150617926 hasConcept C2778570526 @default.
- W2150617926 hasConcept C2779923671 @default.
- W2150617926 hasConcept C2780664588 @default.
- W2150617926 hasConcept C71924100 @default.
- W2150617926 hasConceptScore W2150617926C141105273 @default.
- W2150617926 hasConceptScore W2150617926C159654299 @default.
- W2150617926 hasConceptScore W2150617926C16005928 @default.
- W2150617926 hasConceptScore W2150617926C203014093 @default.
- W2150617926 hasConceptScore W2150617926C207480886 @default.
- W2150617926 hasConceptScore W2150617926C2775933838 @default.
- W2150617926 hasConceptScore W2150617926C2777995640 @default.
- W2150617926 hasConceptScore W2150617926C2778168870 @default.
- W2150617926 hasConceptScore W2150617926C2778564945 @default.
- W2150617926 hasConceptScore W2150617926C2778570526 @default.
- W2150617926 hasConceptScore W2150617926C2779923671 @default.
- W2150617926 hasConceptScore W2150617926C2780664588 @default.
- W2150617926 hasConceptScore W2150617926C71924100 @default.
- W2150617926 hasIssue "5" @default.
- W2150617926 hasLocation W21506179261 @default.
- W2150617926 hasLocation W21506179262 @default.
- W2150617926 hasOpenAccess W2150617926 @default.
- W2150617926 hasPrimaryLocation W21506179261 @default.
- W2150617926 hasRelatedWork W2020556773 @default.
- W2150617926 hasRelatedWork W2085552858 @default.
- W2150617926 hasRelatedWork W2107604311 @default.
- W2150617926 hasRelatedWork W2150617926 @default.
- W2150617926 hasRelatedWork W2547267914 @default.
- W2150617926 hasRelatedWork W2781798643 @default.
- W2150617926 hasRelatedWork W2909037035 @default.
- W2150617926 hasRelatedWork W3028173815 @default.
- W2150617926 hasRelatedWork W3193728213 @default.
- W2150617926 hasRelatedWork W86134801 @default.
- W2150617926 hasVolume "21" @default.
- W2150617926 isParatext "false" @default.
- W2150617926 isRetracted "false" @default.
- W2150617926 magId "2150617926" @default.
- W2150617926 workType "article" @default.